Preclinical News and Research

RSS

Immune dysfunction persists after combined TB and HIV therapy

The immune system remains seriously out-of-whack – in an inflammatory state of overactivation and impaired functionality – following the international gold standard for treating people with latent tuberculosis (TB) and HIV, a team at Texas Biomedical Research Institute reports in Nature Communications.

14 Jan 2026

New chemistry revives neurokinin-1 receptor as depression treatment target

For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major depressive disorder.

14 Jan 2026

Disease-responsive nanoparticles enable ghrelin mRNA therapy in osteoarthritis

Nitin Joshi, PhD, and Jingjing Gao, PhD, of the Department of Anesthesiology at Mass General Brigham, are the co-senior authors of a paper published in Nature Nanotechnology, "A disease-severity-responsive nanoparticle enables potent ghrelin mRNA therapy in osteoarthritis." Mahima Dewani, PhD, is the lead author of this study.

14 Jan 2026

Cannabidiol could become a therapeutic tool for fetal alcohol spectrum disorder

Cannabidiol (CBD) could become a therapeutic tool to address some of the most frequent and disabling consequences of fetal alcohol spectrum disorder (FASD), a condition caused by alcohol exposure during pregnancy.

14 Jan 2026

Preclinical study reveals potential new treatment for severe liver fibrosis

Researchers at McMaster University are leading preclinical studies into a novel drug candidate developed by Espervita Therapeutics that has the potential to prevent and reverse liver fibrosis - a dangerous, disease-induced build-up of scar tissue in the liver that often leads to cancer.

13 Jan 2026

Biohybrid skin graft: A fluorescent window into internal health monitoring

Wearable health devices, such as smartwatches, have become commonplace, enabling the continuous monitoring of physiological signals at the skin's surface.

13 Jan 2026

OutSee completes seed funding round and establishes partnership with o2h discovery for lead drug target candidate

OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced the closure of its £2.5 M seed funding round.

12 Jan 2026

New publication describes the chemical journey of non-hormonal male birth control pill

A newly published manuscript authored by Dr. Gunda Georg, YourChoice Therapeutics and Columbia University Medical Center describes the chemical journey of YCT-529, a non-hormonal male birth control pill, and the promising molecular science behind it.

12 Jan 2026

Resistance to rezatapopt: New TP53 mutations identified in cancer patients

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics.

12 Jan 2026

Targeting IDO1 for cancer: Novel degraders show promise in preclinical studies

Cancer cells employ a variety of strategies to evade the immune system, and modern immunotherapies aim precisely at these escape mechanisms.

9 Jan 2026

ICSA 2025: Infection's role in cellular senescence, inflammation, and aging

A new meeting report was published in Volume 17, Issue 12 of Aging-US on December 23, 2025, titled "Cellular senescence meets infection: highlights from the 10th annual International Cell Senescence Association (ICSA) conference, Rome 2025."

8 Jan 2026

Bowel preparation for colonoscopies may temporarily alter gut balance, preclinical study suggests

New preclinical research suggests that bowel preparation procedures for colonoscopies may temporarily alter gut balance, culminating in unappreciated effects in patients with compromised gastrointestinal health.

8 Jan 2026

Recent advances in CAR-NK cell therapy could revolutionze cancer treatment

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, manufacturing complexity, and limited effectiveness against solid tumors.

8 Jan 2026

Biodegradable pill improves medication adherence monitoring

In an advance that could help ensure people are taking their medication on schedule, MIT engineers have designed a pill that can report when it has been swallowed.

8 Jan 2026

Why promising microbiome therapies rarely work in patients

Addressing the microbiome's translational gap involves understanding biological complexity and developing function-driven, patient-specific interventions.

8 Jan 2026

Stimulating immune cells could offer new treatment for nerve injury pain

Researchers at The University of Texas MD Anderson Cancer Center have discovered that targeting a specific immune process could help improve recovery after nerve injury and reduce chronic pain.

7 Jan 2026

Reprogramming immunity to protect beta cells in type 1 diabetes

In the battle against type 1 diabetes (T1D), one researcher at the Medical University of South Carolina (MUSC) is leading a bold new front. With $1 million in funding from Breakthrough T1D, the leading global T1D research and advocacy organization, Leonardo Ferreira, Ph.D., assistant professor of Pharmacology and Immunology, and his collaborators at partnering institutions will explore a new approach to treating – and potentially curing – the disease.

7 Jan 2026

Injectable nanomaterial reduces secondary brain injury after ischemic stroke

When a person suffers a stroke, physicians must restore blood flow to the brain as quickly as possible to save their life.

7 Jan 2026

BATF2: A novel tumor suppressor silenced by glutamine in head and neck cancer

A novel tumor suppressor, BATF2, can be silenced by factors in the tumor microenvironment, leading to a reduced immune response in five preclinical models of head and neck cancer, according to researchers from The University of Texas MD Anderson Cancer Center.

7 Jan 2026

Gene therapy breakthrough could provide hope for millions living with chronic pain

A preclinical study uncovered a new gene therapy that targets pain centers in the brain while eliminating the risk of addiction from narcotics treatments, a breakthrough which could provide hope for the more than 50 million Americans living with chronic pain.

7 Jan 2026